REGENXBIO Secures FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For RGX-121 Gene Therapy For Hunter Syndrome
Portfolio Pulse from Benzinga Newsdesk
REGENXBIO has secured FDA Regenerative Medicine Advanced Therapy (RMAT) designation for its RGX-121 gene therapy for Hunter Syndrome. The RMAT designation aims to expedite drug development and review processes for promising new treatments.
May 23, 2023 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
REGENXBIO's stock may benefit from the FDA RMAT designation for its RGX-121 gene therapy for Hunter Syndrome, as it expedites drug development and review processes.
The FDA RMAT designation for REGENXBIO's RGX-121 gene therapy for Hunter Syndrome is a positive development for the company. This designation is designed to expedite the drug development and review processes for promising new treatments, which may lead to faster approval and commercialization. As a result, this news is likely to have a positive impact on REGENXBIO's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100